| Metric | Q2-26 | Q2-25 |
|---|---|---|
| Revenue | 336.31 | 274.11 |
| Gross Profit | 172.54 | 151.58 |
| Net Income | 25.30 | 42.21 |
| Diluted EPS | 0.53 | 0.86 |
- Net Income YoY
- -40.1%
Key highlights
- Quarterly revenue reached $336.31 million, compared to $274.11 million in the prior year period
- Net income decreased to $25.30 million, a 40.1% year-over-year decline from $42.21 million
- Diluted earnings per share fell to $0.53, down from $0.86 in the second quarter of the previous year
- Gross profit rose to $172.54 million, up from $151.58 million in the year-ago quarter
- The balance sheet expanded via a $1.19 billion acquisition funded by new term loans and senior notes
How the Period Went
Prestige Consumer Healthcare recorded total revenues of $336.31 million for the second quarter of fiscal 2027, representing a substantial increase from the $274.11 million reported in the same period last year. This top-line growth was supported by a $1.19 billion acquisition that scaled the company's operational footprint. However, the bottom line saw significant pressure as net income dropped 40.1% to $25.30 million, compared to $42.21 million in the prior year. This divergence highlights a period of aggressive expansion where immediate profitability, reflected in the diluted EPS of $0.53 versus $0.86, was traded for long-term scale and market positioning.
Margins and Profitability
While gross profit increased to $172.54 million from $151.58 million year-over-year, the company's operating margins faced headwinds from transaction-related costs. The decrease in net income was primarily attributed to higher interest expenses and non-recurring costs associated with the billion-dollar acquisition. Management utilized a combination of new term loans and senior notes to finance the deal, leading to a shift in the capital structure. These financing obligations, coupled with integration expenses, offset the gains from the expanded revenue base during the transition phase, as the company works to realize synergies from its newly acquired assets.
Business Overview
Operating within the specialty and generic drug manufacturing sector, Prestige Consumer Healthcare focuses on over-the-counter (OTC) products. The company manages a diverse portfolio of household brands across North American and International segments, serving diverse end markets from pediatric care to dermatological solutions. By acquiring established brands, the firm aims to leverage its distribution network to drive incremental value. The recent $1.19 billion transaction underscores this strategy, significantly increasing the company's total assets and market presence in the competitive consumer healthcare landscape where scale is critical for maintaining retail shelf space and managing supply chain costs.
Financial Context and Guidance
- The company updated its fiscal 2027 revenue outlook on November 5, 2026, targeting between $1,280 million and $1,290 million
- Adjusted diluted EPS for the full fiscal year is projected to fall within the range of $4.48 to $4.55
- The stock's P/E ratio currently stands at 14.92, while an RSI of 68.8 suggests the security is approaching overbought levels after a 7.55% daily gain
- Prestige reported no significant order backlog as of March 31, 2026, maintaining a high-velocity consumer goods fulfillment model
- Recent performance shows a one-month price appreciation of 16.84%, reflecting market response to the updated guidance and acquisition strategy
Down 9.9% since our story on 5 Nov: $53.28 when we broke it → $48.00 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $49.71 |
|---|---|
| 20 Oct | $49.36 |
| 21 Oct | $47.92 |
| 22 Oct | $49.46 |
| 23 Oct | $47.80 |
| 26 Oct | $48.15 |
| 27 Oct | $47.39 |
| 28 Oct | $47.79 |
| 29 Oct | $48.75 |
| 30 Oct | $49.06 |
| 2 Nov | $49.73 |
| 3 Nov | $49.54 |
| 4 Nov | $53.28 |
| 5 Nov | $44.32 |
| 6 Nov | $42.98 |
| 9 Nov | $43.67 |
| 10 Nov | $44.97 |
| 11 Nov | $44.17 |
| 12 Nov | $45.32 |
| 13 Nov | $46.19 |
| 16 Nov | $48.00 |
| Date | Announcement | Amount |
|---|---|---|
| 06 Aug 2026 | Q1 FY 2027 revenueSource: ir.prestigebrands.com | $265.7 Million |
| 13 May 2026 | Q4 FY 2026 revenueSource: globenewswire.com | $281.6 Million |
| 05 Feb 2026 | Q3 FY 2026 revenueSource: ir.prestigebrands.com | $283.4 Million |
| 06 Nov 2025 | Q2 FY 2026 revenueSource: ir.prestigebrands.com | $274.1 Million |
| 07 Aug 2025 | Q1 FY 2026 revenueSource: ir.prestigebrands.com | $249.5 Million |
| Share price | $53.28 |
|---|---|
| Market cap | $2.5B |
| Revenue (annual) | $1.1B |
| P/E (TTM) | 14.9× |
| 1-month price change | +16.84% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Prestige Consumer Healthcare Inc. announcing second quarter fiscal 2027 financial results.
Track Prestige Consumer Healthcare Inc. live
Get the next Prestige Consumer Healthcare Inc. SEC filing seconds after it lands.



